Concurrent chemoradiotherapy with gemcitabine and cisplatin for pancreatic cancer: From the laboratory to the clinic

International Journal of Radiation Oncology Biology Physics

Volumn 53, Issue 1, 2002, Pages 140-145

  Symon, Zvi ^a   Davis, Mary ^a   McGinn, Cornelius J ^a   Zalupski, Mark M ^b   Lawrence, Theodore S ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cisplatin; Gemcitabine; Pancreas cancer; Radiation; Radiosensitizing agents

Indexed keywords

BIOASSAY; CELLS; ONCOLOGY; RADIATION; TOXICITY; TUMORS;

CONCURRENT RADIATION;

RADIOTHERAPY;

CISPLATIN; GEMCITABINE;

ANALYTIC METHOD; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL SURVIVAL; CLONOGENESIS; CLONOGENIC ASSAY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SCREENING; HUMAN; HUMAN CELL; LABORATORY; OUTPATIENT DEPARTMENT; PANCREAS CANCER; PANCREAS CELL; PRIORITY JOURNAL; RADIOSENSITIZATION;

CISPLATIN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; PANCREATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0036570271     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)02790-0     Document Type: Article

References (29)

1. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma
2. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil
3. Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone
4. Radiotherapy of unresectable pancreatic carcinoma: A six year experience with 104 patients
5. Treatment of locally unresectable cancer of the stomach and pancreas: A randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil - An Eastern Cooperative Oncology Group study
6. ESPAC-1 interim results: A European randomized study to assess the roles of adjuvant chemotherapy (5FU + folinic acid) and adjuvant chemoradiation (40Gy and 5FU) in resectable pancreatic cancer
7. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine
8. A phase I trial of radiation dose escalation with concurrent weekly full dose gemcitabine in patients with advanced pancreatic cancer
9. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
10. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: A regimen with expected early toxicity
11. Synergistic interaction between cisplatin and gemcitabine in vitro
12. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non small cell lung cancer cell lines
13. Combination chemotherapy studies with gemcitabine and etoposide in non- small cell lung and ovarian cancer cell lines
14. Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors
15. Combination chemotherapy studies with gemcitabine
16. Phase II study of gemcitabine and cisplatinum in advanced or metastatic pancreatic cancer
17. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
18. The effect of single versus double-strand substitution on halogenated pyrimidine-induced radiosensitization and DNA strand breakage in human tumor cells
19. Quantitative analysis of dose-effect relationships: The combined effect of multiple drugs or enzyme inhibitors
20. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-beta-d-arabinofuranosylcytosine
21. Pharmacodynamics of cisplatin in human head and neck cancer: Correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo
22. Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2′,2′-difluoro-2′-deoxycytidine (gemcitabine)
23. Production of DNA double-strand breaks by interactions between carboplatin and radiation: A potential mechanism for radiopotentiation
24. Carboplatin enhances the production and persistence of radiation-induced DNA single-strand breaks
25. Expression of ERCC1 antisense RNA abrogates gemcitabine-mediated cytotoxic synergism with cisplatin in human colon tumor cells defective in mismatch repair but proficient in nucleotide excision repair
26. Effect of cisplatin on the clinically relevant radiosensitivity of human cervical carcinoma cells lines
27. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study
28. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma
29. Gemcitabine-cisplatin: A schedule finding study